Athera Biotechnologies completes 24 million SEK financing

Document -

Athera Biotechnologies completes 24 million SEK financing

Athera Biotechnologies AB, a privately held biopharmaceutical company focused on developing a new antibody against cardiovascular diseases, has completed a 24 million SEK financing from a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc Invest. Additional investors are Athera´s Board and management, as well as other investors.
  • License: Media Use
    The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
  • File format: .pdf
Download

Contacts

James Hall

Press contact Chief Executive officer; MD, PhD Chief Executive officer; MD, PhD +46705775300

Carina Schmidt

Press contact Senior Business Advisor, M.Sc. Senior Business Advisor, M.Sc. +46 (0)76-1938190

Related content

Athera Biotechnologies completes 24 million SEK financing

Athera Biotechnologies AB, a privately held biopharmaceutical company focused on developing a new antibody against cardiovascular diseases, has completed a 24 million SEK financing from a consortium led by The Foundation for Baltic and East European Studies (Östersjöstiftelsen), Industrifonden and Linc Invest. Additional investors are Athera´s Board and management, as well as other investors.